CTLA4 and medulloblastoma: We also examined the association between our risk score model and immune checkpoint pathways, focusing on PD-L1 and cytotoxic T-lymphocyte associated protein 4 (CTLA4) since inhibitors targeting these checkpoints have been proposed to be effective in treating medulloblastoma animal models (Pham et al., 2016).